Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/6412
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBUYSE, Marc-
dc.contributor.authorPoplavsky, J.L.-
dc.date.accessioned2007-12-20T16:07:42Z-
dc.date.available2007-12-20T16:07:42Z-
dc.date.issued1995-
dc.identifier.citationBlood coagulation and fibrinolysis, 6. p. S86-S92-
dc.identifier.urihttp://hdl.handle.net/1942/6412-
dc.language.isoen-
dc.publisherLippincott Williams & Wilkins-
dc.titleClinical evaluation of virus safety and inhibitor incidence: statistical considerations-
dc.typeJournal Contribution-
dc.identifier.epageS92-
dc.identifier.spageS86-
dc.identifier.volume6-
dc.bibliographicCitation.oldjcat-
item.contributorBUYSE, Marc-
item.contributorPoplavsky, J.L.-
item.fulltextNo Fulltext-
item.fullcitationBUYSE, Marc & Poplavsky, J.L. (1995) Clinical evaluation of virus safety and inhibitor incidence: statistical considerations. In: Blood coagulation and fibrinolysis, 6. p. S86-S92.-
item.accessRightsClosed Access-
Appears in Collections:Research publications
Show simple item record

Page view(s)

30
checked on May 23, 2023

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.